Related Experiment Video

Updated: May 25, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

[Efficacy of immunosuppressive therapy for children with aplastic anemia]

Ying-Chao Wang1, Chu-Yun Yin, Lei Feng

  • 1Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. yingchaowang152@163.com

Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics
|February 1, 2012
PubMed

Insights

Antithymocyte globulin (ATG) plus cyclosporine A (CsA) combination therapy effectively treats childhood aplastic anemia (AA). Factors like disease duration and bone marrow status influence treatment success, with no observed clonal diseases post-therapy.

Area of Science:

  • Pediatric Hematology
  • Immunosuppressive Therapy
  • Aplastic Anemia Research

Context:

  • Childhood aplastic anemia (AA) is a rare but serious condition.
  • Immunosuppressive therapy (IST) is a cornerstone treatment for AA.
  • Understanding factors influencing IST effectiveness is crucial for optimizing patient outcomes.

Purpose:

  • To evaluate the efficacy and safety of IST in pediatric AA.
  • To identify key factors predicting treatment response in children with AA.

Summary:

  • A retrospective analysis of 55 children with severe aplastic anemia (SAA) and 51 with chronic aplastic anemia (CAA) treated with IST between 2007-2010.
  • Antithymocyte globulin (ATG) plus cyclosporine A (CsA) combination therapy showed significantly higher response rates in both CAA (80%) and SAA (75%) compared to CsA alone (44% and 40%, respectively).
  • No patients developed secondary clonal disorders. Early disease course (<6 months), greater bone marrow hematopoietic area (>40%), absence of severe infections, and early response to G-CSF predicted better outcomes.

Impact:

  • ATG plus CsA combination therapy is a safe and effective treatment for childhood AA.
  • Disease duration, bone marrow reserve, infection status, and early G-CSF response are critical determinants of IST effectiveness in pediatric AA.
  • This study provides valuable insights for tailoring IST strategies in children with aplastic anemia.
Abstract

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...